Further chemotherapy or other drug treatment may be the next step.
TREATING AML
How do we treat
the blood-forming system?
First, control the leukemia. For some people, a donor transplant offers a way to rebuild blood formation and add an immune effect against leukemia.
INITIAL AML TREATMENT1 of 4
Reduce the leukemia.
Chemotherapy can kill leukemia cells or stop them multiplying. It can also damage healthy blood-forming cells, so blood counts may fall during treatment.
What does “induction” mean?+
Induction is the initial treatment aimed at achieving remission. Some people receive intensive chemotherapy; others receive less-intensive combinations, often with targeted medicines. Treatment may require more than one cycle.
AML subtype, genetic findings, health and treatment goals guide the choice. Acute promyelocytic leukemia (APL) has a distinct treatment approach, commonly using all-trans retinoic acid and arsenic trioxide.
What are the medicines doing inside a cell?+
Different drugs act differently. Cytarabine, one AML chemotherapy, is activated inside cells and interferes with DNA synthesis. Other medicines damage DNA or target particular proteins and survival pathways.
These medicines do not simply repair the leukemia’s original DNA changes. The picture shows effects on cell populations, not the molecular mechanism of a specific regimen.
Why are transfusions and infection care needed?+
AML and its treatment can both reduce functional blood cells. Transfusions, infection prevention and prompt infection treatment support the person while blood formation is impaired.
LOOK AGAIN, MORE CLOSELY2 of 4
Remission is not the same as cure.
The team reviews marrow, blood counts and other findings. Measurable residual disease (MRD) testing can look for leukemia below the level routine microscopy detects.
MRD-negative means “not detected by this test.” It does not prove that every leukemia cell is gone. More treatment is usually needed after remission to lower the risk of relapse.
THE PATH IS INDIVIDUAL
Weigh relapse risk, response, health, donor options and the person’s goals.
The next two steps follow the transplant path. Donor searches can begin early, while initial AML treatment is underway.
A closer look at remission and MRD+
Complete remission generally includes fewer than 5% marrow blasts, no circulating blasts or disease outside the marrow, and recovery of neutrophils and platelets to defined thresholds. Other response categories allow incomplete blood-count recovery.
MRD may be assessed by flow cytometry or an appropriate molecular test. Interpretation depends on the marker, sample, timing and method. Some persistent mutations reflect clonal hematopoiesis rather than residual AML.
If AML persists or returns, the team reassesses treatment; this diagram is not a mandatory sequence or an individual recommendation.
JUST BEFORE TRANSPLANT3 of 4
A separate job: conditioning.
Conditioning is the planned treatment before donor cells are infused. It uses chemotherapy, sometimes with radiation, to help control leukemia and suppress the recipient’s immune system so donor cells can establish themselves.
INITIAL AML THERAPYAim for remission.
TRANSPLANT CONDITIONINGPrepare for the donor graft.
The marrow is not surgically removed. Donor blood-forming stem cells will arrive through the bloodstream.
Is conditioning always very high-dose chemotherapy?+
No. Myeloablative, reduced-intensity and nonmyeloablative regimens differ in their effects on marrow and immunity. The choice balances disease control with the person’s ability to tolerate treatment.
Lower-intensity conditioning does not eliminate all recipient marrow cells. The donor immune effect is an important part of disease control.
Can chemotherapy also be given after transplant?+
Yes. Some protocols use post-transplant cyclophosphamide (PTCy) after donor-cell infusion to help prevent graft-versus-host disease. Its timing and purpose differ from the initial AML treatment and the pre-transplant conditioning.
INFUSION → ENGRAFTMENT4 of 4
Build a new source of blood cells.
On transplant day, often called Day 0, donor stem cells are infused through an IV. They travel to the marrow. Engraftment means they begin producing new blood cells.
Blood-count recovery ≠ full immune recovery.
Engraftment often takes a few weeks. Immune recovery takes much longer—months to years—and varies between people.
How can the donor’s immune cells help?+
Donor immune cells can recognize and attack remaining leukemia cells. This is the graft-versus-leukemia effect.
They can also attack healthy recipient tissues, causing graft-versus-host disease (GVHD). Prevention and monitoring aim to balance these effects. Engraftment does not guarantee cure; follow-up also watches for relapse, infection and other complications.
Why “bone marrow” and “stem cell” transplant?+
The donated cells may come from peripheral blood, bone marrow or cord blood. In each case, blood-forming stem cells are infused into a vein. “Allogeneic” means they come from another person.
THE CONNECTION
A donor brings blood-forming cells and a new immune system. Next, explore how a transplant team evaluates the match.